Core Viewpoint - The company expects a significant decline in net profit for the fiscal year 2025, projecting a range of 27.2 million to 39.3 million yuan, which represents a decrease of 35% to 55% compared to the previous year [1] Financial Performance - The net profit attributable to shareholders is forecasted to be between 27.2 million and 39.3 million yuan, reflecting a year-on-year decline of 35% to 55% [1] - The net profit after deducting non-recurring gains and losses is estimated to be between 20.1 million and 29.1 million yuan, also indicating a decrease of 35% to 55% year-on-year [1] Expense Analysis - The company has increased its efforts in developing the formulation market, leading to a rise in sales expenses [1] - Management expenses have increased due to payments made for intermediary fees related to restructuring [1] - Research and development expenses have risen as the company continues to invest in new product development [1] Other Income - There has been a reduction in government subsidies related to daily operational activities, resulting in a decrease in other income [1]
科源制药：预计2025年净利润同比下降35%-55%